ASX ANNOUNCEMENT

FebriDx® Commercial Traction Continues to Advance Across Priority U.S. Accounts

Key points

- **Lumos expands FebriDx® live sites to 215 (previously 170) and sites under evaluation to 405 (previously 350).**
- **Two new U.S. urgent care groups within the top 100, each owned and operated by major U.S. health systems, have moved into the network rollout stage, with FebriDx® to be deployed across more than 40 combined sites.**
- **Two additional top 100 urgent care groups, also owned and operated by major U.S. health systems, are now progressing with clinical and economic validation across more than 45 sites.**
- **Lumos continues to execute its strategy of prioritising the top 100 U.S. urgent care groups, which represent an estimated 40% of total U.S. urgent care sites, with advanced discussions progressing.**

MELBOURNE, Australia (15th September 2026) – Lumos Diagnostics Holdings Ltd (ASX:LDX, "Lumos" or the "Company"), a leader in rapid, point-of-care diagnostic technologies, is pleased to provide an update on the progress of its U.S. commercialisation strategy for FebriDx® across its priority top 100 urgent care groups target list. This update builds on investor updates released to ASX in July (21 July 2026 and 27 July 2026).

Commercial progression across priority accounts:

Lumos continues to utilise a four-stage commercial framework to help track and communicate how accounts are advancing. This framework provides investors with a clear way to understand how priority accounts progress from initial engagement through to scaled, protocol-driven use of FebriDx®:

- **Qualified opportunities** - priority accounts identified and engaged based on patient volume, payer mix, strategic fit and network scale.

- **Evaluation Phase: Clinical and economic validation** - targeted clinical performance, reimbursement, workflow and health-economic assessment activities conducted across one or more sites to support broader adoption decisions.

- **Implementation Phase I: Network rollout** - deployment across multiple sites within an account following successful validation of clinical utility, operational fit and reimbursement readiness.

- **Implementation Phase II: Standardised adoption** - FebriDx® becomes embedded in standing orders, triage protocols or routine clinical pathways, supporting repeat ordering and scaled utilisation across the account.

Pipeline Metrics - Strong Commercial Traction:

<table>
<tr><td></td><td colspan="4">IN EVALUATION
Clinical & economic validation underway</td></tr>
<tr><td>POST QUALIFICATION PIPELINE PHASES</td><td>Sites in active evaluation</td><td colspan="2">Est. ARI visits per annum[1]</td><td>Urgent care groups engaged, incl. Top 10,25 and 30</td></tr>
<tr><td>Evaluation Phases:[3]
Clinical & Economic Validation</td><td>405</td><td colspan="2">1.6m–2.2m</td><td>5 in Top 100</td></tr>
<tr><td rowspan="3"></td><td colspan="4">LIVE & SCALING
Network rollout in market</td></tr>
<tr><td>Live sites</td><td>States covered</td><td>Est. ARI visits per annum[1]</td><td>Payment coverage at US$41.38/test</td></tr>
<tr><td>Implementation Phases:
Phase I: Network Rollout
Phase 2: Standardised Adoption</td><td>215</td><td>26</td><td>0.9m-1.2m</td><td>>90%[2]</td></tr>
<tr><td colspan="4">Includes two new Top 100 urgent care groups. All achieved in under four months</td></tr>
</table>

[1]Average ARI (acute respiratory illness) visits per US urgent care site: ~4,000–5,500 per year (~12–17 per day) Derived from: UCA average visit volume of ~34 patients/day/site (2025), annualized to ~12,400 visits/site/year, multiplied by respiratory-related illness share of ~35%–40% of urgent care visits (the single largest visit category).Sources: Urgent Care Association, Urgent Care Data (2025); Health Care Cost Institute, "Respiratory-Related Illness is the Top Reason People Use Urgent Care" (analysis of 73M commercial urgent care visits, 2018–2022).

[2] As reported as at 27 July 2026. Reimbursement coverage data will be provided at a frequency determined by formal reporting from Acuity MD.

[3] Metrics in the table above for the Evaluation Phases only include sites under active engagement i.e. performing clinical & economic validation. Qualified Opportunities, are in addition to these metrics, and include a significant number of sites identified by Lumos and its partners as potential FebriDx customers, including accounts outside the Top 100.

Commercial traction update:

Since the July updates, two additional top 100 U.S. urgent care groups, each owned and operated by major U.S. health systems, have committed to rolling out FebriDx® across more than 40 sites in aggregate, moving these accounts into the network rollout stage.

These deployments further validate Lumos' strategy of partnering with scaled urgent care providers and integrated health systems, where FebriDx® can be embedded into frontline clinical pathways for patients presenting with symptoms of acute respiratory infection. In these settings, FebriDx® has the potential to support more informed prescribing decisions, antimicrobial stewardship initiatives, patient flow efficiency and appropriate referral or escalation pathways.

The two new accounts comprise:

- A large, integrated regional health system with a broad network of hospital, outpatient and community care services, including extended-hours, walk-in urgent care centres treating non-life-threatening illness and injury.

- A leading academic medical centre and health system, operating convenient care, urgent care and advanced urgent care services, providing walk-in access and serving as an important ambulatory entry point into a broader specialist, imaging and hospital network.

This framework aligns to the pathway demonstrated with Lumos' existing customer, WellStreet Urgent Care ("WellStreet"). Following a successful initial pilot, that program expanded to 44 sites and established a pathway for broader deployment across WellStreet's network of more than 165 sites.

Doug Ward, Chief Executive Officer of Lumos Diagnostics, said: *"Securing two further top 100 urgent care groups, both backed by major U.S. health systems, is a clear signal that FebriDx® is earning a place in frontline respiratory care. These are sophisticated organisations that evaluate diagnostics on clinical utility, workflow fit and economics before committing sites, and they are now moving into rollout ahead of the respiratory season. Pleasingly, FebriDx® is now deployed across 215 live sites, including 44 WellStreet sites, with a further 405 sites in the evaluation stage."*

"Just as importantly, they are following the same path we established with WellStreet – pilot, validate, then expand. The repeatability of this model provides us with a strong foundation for scaling our top 100 urgent care group strategy with confidence."

In addition, two further top 100 U.S. urgent care groups, also owned and operated by major U.S. health systems, are currently progressing clinical and economic validation of FebriDx® across more than 45 sites in aggregate. These accounts comprise:

- A multi-state, faith-based and community-focused health system with urgent care services spanning several local markets, providing both in-person and virtual access for patients with minor illnesses and injuries.

- A large Pacific Northwest health system operating a consumer-oriented urgent care network with extended hours and seven-day access, treating common acute presentations including respiratory infections, influenza-like illness, sore throat, colds and other minor conditions.

Validation activities across these accounts include assessment of clinical performance, reimbursement, workflow integration and health-economic impact, which will inform decisions on broader deployment.

Doug Ward added: *"Clinical and economic validation is the gateway to scale in these networks, and having two more health-system-owned groups running that work across more than 45+ sites adds to the depth in our pipeline."*

"Collectively, these four groups represent a meaningful step forward against our top 100 urgent care target list, and they reflect growing recognition that rapid differentiation of bacterial from viral acute

respiratory infection can improve both patient management and antibiotic stewardship at the point of care."

Consistency with prior market communication

This announcement is intended to provide information for the FebriDx® commercial pipeline that is consistent with the Company's previously disclosed commercial metrics. Lumos will continue to report progress in a consistent manner as published in the investor presentation released on 27 July 2026, including site growth, geographic expansion and the use of average ARI visits per site as a benchmark for the potential ARI-related commercial opportunity.

At the same time, the Company expects to continue refining how it communicates account maturity by expanding the dashboard associated with qualified opportunities, clinical and economic validation, network rollout and standardised adoption phases, so investors can better assess how individual priority accounts are evolving over time.

All FebriDx® sales in the U.S. are made through Lumos' exclusive distribution partner, Phase Scientific, as disclosed to the ASX on 16 July 2025, and Lumos recognises FebriDx® revenue when product is shipped from Lumos to Phase Scientific.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:
Haley Chartres – Australia
H^CK Director
haley@hck.digital
+61 423 139 163

Investor Contact:
George Kopsiaftis
IR Specialist, IR Department
ir@lumosdiagnostics.com
+61 409 392 687

Company Registered Office:
Lumos Diagnostics Holdings Ltd
Suite 2, Level 11
385 Bourke Street
Melbourne VIC 3000
info@lumosdiagnostics.com
+61 3 9087 1598